Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2026—NanoSomix and Beckman Coulter Diagnostics are collaborating to explore the development of next-generation immunoassays for neurodegenerative diseases. The companies share an interest in addressing challenges in detecting low-abundance, brain-specific biomarkers in blood.
October 2026—Epredia has launched sales of the SlideMate thermal slide printer, designed to help clinical laboratories protect tissue samples, strengthen sample traceability, and streamline workflow efficiency during cancer diagnosis.
October 2026—The FDA has granted approval for a tumor-only indication for Tempus AI’s xT CDx next-generation sequencing platform. Tempus xT CDx is a 648-gene, tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux (cetuximab) and Vectibix (panitumumab).
October 2026—The FDA has cleared the Visby Medical Flu and COVID-19 at-home PCR test. It provides results for COVID-19 and influenza A/B in 30 minutes. The test will be eligible for flexible spending and health savings account reimbursement.
October 2026—Thermo Fisher Scientific has launched the Thermo Scientific LabLink 360 Quality Assurance software, designed to help clinical laboratories simplify quality control workflows, accelerate QC review and decision-making, improve visibility into QC performance, and manage QC operations.
October 2026—Bio-Rad Laboratories launched its QX700 system-compatible Vericheck ddPCR kit portfolio for quality control workflows in advanced cell and gene therapy development and other biopharma applications. The portfolio includes Vericheck ddPCR Mycoplasma detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification kits.
October 2026—Siemens Healthineers’ Atellica Hema 580 analyzer is now available to U.S. laboratories. Designed for mid- to high-volume labs, the analyzer features proprietary 360-degree continuous sample mixing and can produce test results in as few as 30 seconds, with advanced reticulocyte and platelet parameters available within 60 seconds.
October 2026—Labcorp has launched the Marker by Labcorp Genetic Health Panel, designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions. Available through Labcorp OnDemand, the panel analyzes 163 genes associated with hereditary cancer, cardiovascular conditions, and metabolic conditions.
September 2026—The Digital Pathology Association’s annual meeting, Pathology Visions 2026, is taking place October 16–18 in San Diego. Join the Digital Pathology Association for three days of education, collaboration, and the latest advancements in digital pathology and AI. Connect with more than 1,000 pathologists, researchers, laboratory leaders, health care professionals, and industry innovators who are driving the next era of precision medicine.
September 2026—Horiba has launched Yumivet, its new veterinary diagnostics brand, and introduced the Yumivet VH2500 hematology analyzer.
